Cargando…

Eribulin mesylate exerts antitumor effects via CD103

Eribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor effects by modifying the tumor environment. Although ERB ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oya, Kazumasa, Nakamura, Yoshiyuki, Watanabe, Rei, Tanaka, Ryota, Ichimura, Yuki, Kubota, Noriko, Matsumura, Yutaka, Tahara, Hideaki, Okiyama, Naoko, Fujimoto, Manabu, Nomura, Toshifumi, Fujisawa, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228394/ https://www.ncbi.nlm.nih.gov/pubmed/37261089 http://dx.doi.org/10.1080/2162402X.2023.2218782

Ejemplares similares

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
por: Oya, Kazumasa, et al.
Publicado: (2021)

Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma
por: Nakamura, Yoshiyuki, et al.
Publicado: (2020)

Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6
por: Tanaka, Ryota, et al.
Publicado: (2020)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Honey and Chamomile Activate Keratinocyte Antioxidative Responses via the KEAP1/NRF2 System
por: Ogawa, Tatsuya, et al.
Publicado: (2020)

PD-1 Regulates Passive Anaphylaxis: A Possible Role of the Mast Cell Intracellular Inhibitory Signal
por: Ogawa, Tatsuya, et al.
Publicado: (2021)

Successful Treatment of Acrodermatitis Continua of Hallopeau with an Anti-IL-17A Agent
por: Inoue, Sae, et al.
Publicado: (2021)

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
por: Agoulnik, Sergei I, et al.
Publicado: (2014)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
por: Fujisawa, Yasuhiro, et al.
Publicado: (2018)

Loricrin and NRF2 Coordinate Cornification
por: Ishitsuka, Yosuke, et al.
Publicado: (2021)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Nodulocystic Basal Cell Carcinoma Arising Directly from a Seborrheic Keratosis: A Rare Case Report
por: Shibao, Kana, et al.
Publicado: (2016)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
por: Ishizaka, Takahiro, et al.
Publicado: (2023)

Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil
por: Kurata, Toru, et al.
Publicado: (2018)

Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies
por: Okiyama, Naoko, et al.
Publicado: (2019)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
por: Koczywas, M, et al.
Publicado: (2014)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
por: Byun, Kyung-Do, et al.
Publicado: (2016)

Skin T cells maintain their diversity and functionality in the elderly
por: Koguchi-Yoshioka, Hanako, et al.
Publicado: (2021)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma
por: Miki, Shunichiro, et al.
Publicado: (2018)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
por: Adamo, Vincenzo, et al.
Publicado: (2019)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
por: Iwata, Masahiro, et al.
Publicado: (2022)

Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma
por: Nakano, Tomoyuki, et al.
Publicado: (2021)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
por: Ko, Hyemi, et al.
Publicado: (2022)

TB-06 Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma
por: Nakano, Tomoyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lu4qlnqnhelch2v4bqqt98h82c